Wave Life Sciences announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave’s emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company’s best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences Releases Updated Corporate Overview
- Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
- Wave Life announces approval of first CTA for RestorAAtion-2 trial
- Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)